{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/64c1fb4a8e16bd00116ffd75/69c5c1f8f4bf09c599ae04f8?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Ozempic Just Got Cheap Enough to Change the Entire World","description":"<p>A blockbuster drug collapsing from $1,000 to $15 looks like a pricing story. It isn’t. It is a signal that control over human behavior, demand, and consumption is shifting fast. Between generics, new science, and AI-driven optimization, entire industries tied to addiction, food, and habit-driven spending may face structural decline. This episode breaks down why this disruption was inevitable and what happens next.</p><p><br></p><p>CHAPTERS</p><p>00:00 $1,000 drug drops to $15 overnight</p><p>00:30 The real story behind the price collapse</p><p>00:56 Patent cliff and global generics surge</p><p>01:40 Pricing pressure spreads beyond India</p><p>02:30 Who controls the pipeline</p><p>03:40 New research changes expectations</p><p>05:20 AI enters dosing and drug discovery</p><p>06:30 This becomes an economic story</p><p>07:00 Workforce and GDP implications</p><p>08:15 Spending shifts across industries</p><p>09:15 What breaks next</p><p><br></p><p>SOURCES</p><p>- Affordable GLP-1 Options Emerging in India and Beyond (CNBC): https://www.cnbc.com/2026/03/23/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html</p><p>- Global Impact of Ozempic Generics Expanding to China and Canada (NYT): https://www.nytimes.com/2026/03/19/health/ozempic-wegovy-generic-india-china-canada.html</p><p>- Worldwide Reactions to Cheaper GLP-1 Drugs (BBC Analysis): https://www.bbc.com/news/articles/cx2g4411en3o</p><p>- AI Optimizing Weight Loss Outcomes: https://www.sciencedirect.com/science/article/abs/pii/S2405457725003821</p><p>- Personalized Semaglutide Therapy with Artificial Intelligence: https://ai.jmir.org/2026/1/e86960</p><p>- Breakthroughs in GLP-1 Drug Engineering: https://www.sciencedirect.com/science/article/pii/S1359644625000467</p><p>- Cutting-Edge Ozempic Alternatives in Research: https://www.nature.com/articles/s41586-025-08683-y</p><p>- Stanford Research on New Ozempic Rivals: https://med.stanford.edu/news/all-news/2025/03/ozempic-rival.html</p><p>- GLP-1 Demand and Consumer Purchase Data (Numerator Report): https://www.numerator.com/press/numerator-glp-1-hub-reveals-purchase-trends-from-30k-consumers/</p><p>- Marketing Shifts in the Weight-Loss Drug Space: https://journals.sagepub.com/doi/10.1177/00222437251412834</p><p>- Ozempic Frenzy: What’s Coming Next in Weight-Loss Drugs (WSJ): https://www.wsj.com/health/pharma/weight-loss-drug-frenzy-whats-here-and-whats-likely-coming-next-a84ef28b?mod=hp_lead_pos7</p><p>- GLP-1 Market Expansion Across Global Economies: https://www.arabnews.com/node/2637254/world</p><p>- New Findings on Stopping Ozempic and Mounjaro Use (Science Daily): https://www.sciencedaily.com/releases/2026/03/260319044648.htm#:~:text=03/260319044648.htm</p><p>- GLP-1 Insights from Griffith University Study (Science Daily): https://www.sciencedaily.com/releases/2026/03/260322020250.htm</p>","author_name":"Neeta Bidwai"}